Thyroid Treatment Recommendations
Hypothyroidism Treatment
L-thyroxine (levothyroxine) monotherapy is the definitive treatment for hypothyroidism, with dosing tailored to age and cardiac status. 1
Initial Dosing Strategy
Young healthy adults with overt hypothyroidism: Start with full replacement doses (typically 1.5-1.8 mcg/kg/day) 1, 2. This approach achieves euthyroidism quickly without unnecessary titration delays.
Patients over 50-60 years or with coronary heart disease: Begin with 50 mcg daily 1. This cautious approach prevents cardiac complications, as overtreatment can precipitate atrial fibrillation and worsen ischemic heart disease.
Subclinical hypothyroidism: Use lower initial doses of 25-75 mcg daily, adjusted based on TSH elevation degree 1. Many patients with mildly elevated TSH (4-10 mU/L) may not require treatment, particularly elderly patients 3.
Administration Guidelines
- Take L-thyroxine with water 30-60 minutes before breakfast OR at bedtime 4 hours after the last meal 1
- Avoid concurrent ingestion with substances that impair absorption (calcium, iron, proton pump inhibitors, soy products)
- Store properly per product insert
Monitoring
- Recheck TSH within 4-8 weeks after initiation or dose adjustment 1
- Target TSH within normal reference range (not specifically low-normal) for non-pregnant patients 1
- Once stable, annual monitoring is sufficient
Special Populations
Pregnancy: This requires aggressive management with specific TSH targets:
- First trimester: TSH <2.5 mIU/L 1
- Second trimester: TSH <3.0 mIU/L 1
- Third trimester: TSH <3.5 mIU/L 1
- Increase levothyroxine dose by 30% immediately upon pregnancy confirmation 2
- Monitor TSH every 4 weeks during first 20 weeks, then at 26-32 weeks 1
What NOT to Use
Desiccated thyroid hormone should not be used for hypothyroidism treatment 1. There is no evidence supporting its superiority over L-thyroxine monotherapy, and it provides inconsistent T4/T3 ratios.
L-thyroxine/L-triiodothyronine combinations should not be used in pregnant women or those planning pregnancy 1. Even in non-pregnant patients, adding T3 provides no benefit for persistent symptoms when TSH is normalized 2.
Hyperthyroidism Treatment
Methimazole should be used as first-line antithyroid drug therapy for Graves' disease in virtually all patients, except during first trimester pregnancy when propylthiouracil is preferred. 4
Treatment Modalities
Three definitive options exist for hyperthyroidism, each with distinct indications:
1. Antithyroid Drugs (ATDs)
Methimazole is the preferred agent because:
- More effective than propylthiouracil
- Once-daily dosing improves adherence
- Lower risk of serious hepatotoxicity
Propylthiouracil is reserved for:
- First trimester of pregnancy (methimazole has teratogenic effects: aplasia cutis, choanal/esophageal atresia) 4
- Thyroid storm
- Minor reactions to methimazole in patients refusing radioactive iodine
Critical pregnancy considerations:
- Switch from methimazole to propylthiouracil immediately upon pregnancy confirmation in first trimester 4
- Switch back to methimazole after first trimester 4
- For breastfeeding: methimazole is preferred over propylthiouracil due to hepatotoxicity risk 4
2. Radioactive Iodine (¹³¹I)
Indications:
- Definitive therapy for Graves' disease
- Toxic nodular goiter
- Patients not achieving remission with ATDs
Absolute contraindications:
- Pregnancy (causes fetal athyreosis after 10-11 weeks gestation) 4
- Active breastfeeding (wait ≥6 weeks after lactation stops) 4
Follow-up protocol:
- Assess free T4 and total T3 within 1-2 months 4
- If thyrotoxic, continue monitoring every 4-6 weeks 4
- Retreatment indicated if hyperthyroidism persists at 6 months or minimal response at 3 months 4
- Most patients develop hypothyroidism between 2-6 months, requiring levothyroxine replacement 4
Radiation safety: Physician must provide written precautions; if patient cannot follow them, choose alternative therapy 4
3. Surgery
Reserved for:
- Patients refractory to multiple ¹³¹I treatments 4
- Large goiters causing compressive symptoms
- Suspicion of malignancy
- Patient preference when expert surgical care available 5
Treatment Selection Algorithm
- Graves' disease, non-pregnant: Methimazole OR radioactive iodine (patient preference, considering age and fertility plans)
- Graves' disease, first trimester pregnancy: Propylthiouracil
- Graves' disease, second/third trimester pregnancy: Methimazole
- Toxic nodular goiter: Radioactive iodine or surgery (ATDs only for temporary control)
- Thyroiditis (including postpartum): Beta-blockers for symptom control; self-limited, no ATDs needed 6
Common Pitfalls
- Do not use propylthiouracil outside first trimester pregnancy due to potentially fatal hepatotoxicity 4
- Do not administer radioactive iodine without confirming non-pregnancy status and ensuring 6+ weeks since lactation cessation
- Do not overlook transient hCG-mediated TSH suppression in early pregnancy—this does not require ATD therapy 4
- Avoid overtreatment with levothyroxine after radioactive iodine, as residual thyroid function may be nonsuppressible initially 4
Long-term Management
After achieving euthyroidism with any modality, lifelong annual thyroid function testing is mandatory 4. Most patients treated with radioactive iodine eventually develop hypothyroidism requiring permanent levothyroxine replacement.